雄激素受体剪接变异体7在转移性去势抵抗性前列腺癌治疗中的预后价值：系统综述和Meta分析的数据表1
系统综述和Meta分析数据表，评估AR-V7状态对转移性去势抵抗性前列腺癌患者治疗预后的影响，包含1545例患者数据。
基本信息
资源简介
雄激素受体剪接变异体7在转移性去势抵抗性前列腺癌治疗中的预后价值：系统综述和Meta分析的数据表1
【一句话概览】
本数据集是 figshare 公开的结构化表格数据集，收录 1 个文件、合计 1.02 MB，主题涵盖 androgen receptor splice variant 7、prognosis、androgen receptor signaling inhibitors、chemotherapy，可用于统计建模、特征工程与队列分析，CC BY 4.0 许可开放获取。
【数据集背景】
本数据集源站标题为《DataSheet_1_Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.docx》。配套论文《Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants》发表于 Clinical Cancer Research（2011），DOI：10.1158/1078-0432.CCR-11-0728。源站首次发布：2020-11-30。
【数据内容】
源站原始描述：BackgroundThe prognostic value of androgen receptor splice variant 7 (AR-V7) for the treatment response of metastatic castration-resistant prostate cancer (mCRPC) remains unclear. In this study, we aimed to synthesize relevant studies that assessed the prognostic value of AR-V7 status for the treatment response of mCRPC patients treated with androgen receptor signalling inhibitors (ARSis) and chemotherapy. MethodsWe searched the PubMed, Embase, and MEDLINE databases by using the keywords AR-V7 a…
【数据结构与技术规格】
文件数 1 个，合计 1.02 MB。DataSheet_1_Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic R.docx：application/vnd.openxmlformats-officedocument.wordprocessingml.document，1.02 MB。数据集 DOI：10.3389/fonc.2020.562504.s001。
【主题与分类】
源站学科分类：Cancer、Haematological Tumours、Radiation Therapy、Solid Tumours、Oncology and Carcinogenesis not elsewhere classified、Molecular Targets。主题标签：androgen receptor splice variant 7、prognosis、androgen receptor signaling inhibitors、chemotherapy。
【适用方向】
结构化表格数据可直接用于统计建模、特征工程与队列分析。
【获取与许可】
源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Prognostic_Value_of_Androgen_Receptor_Splice_Variant_7_in_the_Treatment_of_Metastatic_Castration-Resistant_Prostate_Cancer_A_Systematic_Review_and_Meta-Analysis_docx/13302803
使用许可：CC BY 4.0（https://creativecommons.org/licenses/by/4.0/）。
规范引用：Wang, Jiaxin; Zhang, Yucong; Wei, Chao; Gao, Xintao; Yuan, Penghui; Gan, Jiahua; et al. (2020). DataSheet_1_Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.docx. Frontiers. Dataset
【使用注意】
· 源站最后修改于 2023-06-01，引用时请注意版本时效。
下载信息
注册下载
需要注册 Kaggle 账号并登录后下载，适合需要跟踪下载记录和使用 API 的用户。
暂未开放公开下载
无需注册即可直接获取公开样本或文档，适合快速预览和评估数据集质量。
免登录有偿下载
公开数据集受托下载与技术交付服务。
提供高速下载与技术交付服务（收技术服务费，非数据销售）
暂未开放当前数据集主要来源为 Kaggle 公开托管，完整影像包建议通过原始链接或 Kaggle API 获取。
使用方式
数据集获取（Figshare）
- 源站标题：DataSheet_1_Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.docx
- DOI：10.3389/fonc.2020.562504.s001
- 发布日期：2020-11-30
- 文件数：1 个
- 文件总体积：1.02 MB
- 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Prognostic_Value_of_Androgen_Receptor_Splice_Variant_7_in_the_Treatment_of_Metastatic_Castration-Resistant_Prostate_Cancer_A_Systematic_Review_and_Meta-Analysis_docx/13302803
命令行下载
curl -L -o "DataSheet_1_Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic R.docx" "https://ndownloader.figshare.com/files/25633505"
文件清单
DataSheet_1_Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic R.docx（1.02 MB）
文件总体积 1.02 MB（源站 API 实测）。
数据说明
BackgroundThe prognostic value of androgen receptor splice variant 7 (AR-V7) for the treatment response of metastatic castration-resistant prostate cancer (mCRPC) remains unclear. In this study, we aimed to synthesize relevant studies that assessed the prognostic value of AR-V7 status for the treatment response of mCRPC patients treated with androgen receptor signalling inhibitors (ARSis) and chemotherapy.
MethodsWe searched the PubMed, Embase, and MEDLINE databases by using the keywords AR-V7 and prostate cancer to identify relevant studies published before 25 September 2019. The main outcomes were prostate-specific antigen (PSA) response, progression-free survival (PFS), and overall survival (OS). Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random effects model. The quality of the included studies was assessed using the Newcastle-Ottawa Quality Assessment Scale.
ResultsA total of 1,545 patients from 21 studies were included. For the mCRPC patients treated with ARSis, AR-V7-positive patients had a lower PSA response rate (OR 6.01, 95% CI 2.88–12.51; P AR-V7 is a potential biomarker of treatment resistance in mCRPC patients. AR-V7-positive mCRPC patients had poorer treatment outcomes than AR-V7-nagetive patients when treated with ARSis. AR-V7-positive patients have better outcomes when treated with taxane than ARSis. Furthermore, the ability of AR-V7 status to predict treatment outcomes varies from different detection methods. The detection of AR-V7 before treatment is important for the selection of treatment modalities for mCRPC patients.
许可
CC BY 4.0
引用
学术使用请引用 DOI 10.3389/fonc.2020.562504.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Prognostic_Value_of_Androgen_Receptor_Splice_Variant_7_in_the_Treatment_of_Metastatic_Castration-Resistant_Prostate_Cancer_A_Systematic_Review_and_Meta-Analysis_docx/13302803）。
数据缺失？
依托陕西、四川两大基地，我们与超过十家三甲医院建立直接合作关系，覆盖合规授权、采集治理、专业标注、数据交付的全流程，为AI医疗团队提供即拿即用的高质量临床数据。
⚡️ 需要数据支持或标注服务？立即联系我们获取专业方案。
